Moreover, as for breast cancer, recent evidence has preliminarily displayed that the genes potentially targeted by miR-200a are enriched in the PD-1 and PD-L1 pathways, indicating the potential ability of miR-200a to regulate those immune checkpoints [33]. The gene discussed is CD274; the disease is breast carcinoma.